Cargando…

Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials

AIM: The aims of this study were to investigate new nano-formulations based on ZnO and Ag nanoparticle (NP) compounds when used against clinical strains of oral gram-positive and gram-negative bacteria, and to examine the stability and behaviour of nano-formulation mixtures in saliva based on differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokrowiecki, Rafal, Wojnarowicz, Jacek, Zareba, Tomasz, Koltsov, Iwona, Lojkowski, Witold, Tyski, Stefan, Mielczarek, Agnieszka, Zawadzki, Pawel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886554/
https://www.ncbi.nlm.nih.gov/pubmed/31819427
http://dx.doi.org/10.2147/IJN.S221608
_version_ 1783474894636318720
author Pokrowiecki, Rafal
Wojnarowicz, Jacek
Zareba, Tomasz
Koltsov, Iwona
Lojkowski, Witold
Tyski, Stefan
Mielczarek, Agnieszka
Zawadzki, Pawel
author_facet Pokrowiecki, Rafal
Wojnarowicz, Jacek
Zareba, Tomasz
Koltsov, Iwona
Lojkowski, Witold
Tyski, Stefan
Mielczarek, Agnieszka
Zawadzki, Pawel
author_sort Pokrowiecki, Rafal
collection PubMed
description AIM: The aims of this study were to investigate new nano-formulations based on ZnO and Ag nanoparticle (NP) compounds when used against clinical strains of oral gram-positive and gram-negative bacteria, and to examine the stability and behaviour of nano-formulation mixtures in saliva based on different compositions of Ag NPs, ZnO NPs and ZnO+x·Ag NPs. Methods: ZnO NPs with and without nanosilver were obtained by microwave solvothermal synthesis. Then, antibacterial activity was evaluated against bacteria isolated from human saliva. Behavior and nanoparticle solutions were evaluated in human saliva and control (artificial saliva and deionized water). Results were statistically compared. RESULTS: The NP mixtures had an average size of 30±3 nm, while the commercial Ag NPs had an average size of 55±5 nm. The suspensions displayed differing antibacterial activities and kinetics of destabilisation processes, depending on NPs composition and fluid types. CONCLUSION: The present study showed that all NPs suspensions displayed significant destabilisation and high destabilisation over the 24 h of the analyses. The agglomeration processes of NPs in human saliva can be reversible.
format Online
Article
Text
id pubmed-6886554
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68865542019-12-09 Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials Pokrowiecki, Rafal Wojnarowicz, Jacek Zareba, Tomasz Koltsov, Iwona Lojkowski, Witold Tyski, Stefan Mielczarek, Agnieszka Zawadzki, Pawel Int J Nanomedicine Original Research AIM: The aims of this study were to investigate new nano-formulations based on ZnO and Ag nanoparticle (NP) compounds when used against clinical strains of oral gram-positive and gram-negative bacteria, and to examine the stability and behaviour of nano-formulation mixtures in saliva based on different compositions of Ag NPs, ZnO NPs and ZnO+x·Ag NPs. Methods: ZnO NPs with and without nanosilver were obtained by microwave solvothermal synthesis. Then, antibacterial activity was evaluated against bacteria isolated from human saliva. Behavior and nanoparticle solutions were evaluated in human saliva and control (artificial saliva and deionized water). Results were statistically compared. RESULTS: The NP mixtures had an average size of 30±3 nm, while the commercial Ag NPs had an average size of 55±5 nm. The suspensions displayed differing antibacterial activities and kinetics of destabilisation processes, depending on NPs composition and fluid types. CONCLUSION: The present study showed that all NPs suspensions displayed significant destabilisation and high destabilisation over the 24 h of the analyses. The agglomeration processes of NPs in human saliva can be reversible. Dove 2019-11-27 /pmc/articles/PMC6886554/ /pubmed/31819427 http://dx.doi.org/10.2147/IJN.S221608 Text en © 2019 Pokrowiecki et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pokrowiecki, Rafal
Wojnarowicz, Jacek
Zareba, Tomasz
Koltsov, Iwona
Lojkowski, Witold
Tyski, Stefan
Mielczarek, Agnieszka
Zawadzki, Pawel
Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title_full Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title_fullStr Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title_full_unstemmed Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title_short Nanoparticles And Human Saliva: A Step Towards Drug Delivery Systems For Dental And Craniofacial Biomaterials
title_sort nanoparticles and human saliva: a step towards drug delivery systems for dental and craniofacial biomaterials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886554/
https://www.ncbi.nlm.nih.gov/pubmed/31819427
http://dx.doi.org/10.2147/IJN.S221608
work_keys_str_mv AT pokrowieckirafal nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT wojnarowiczjacek nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT zarebatomasz nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT koltsoviwona nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT lojkowskiwitold nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT tyskistefan nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT mielczarekagnieszka nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials
AT zawadzkipawel nanoparticlesandhumansalivaasteptowardsdrugdeliverysystemsfordentalandcraniofacialbiomaterials